

Synthesis of pyrazolo[1,5-*a*]pyrimidine derivatives and their antifungal activities against phytopathogenic fungi in vitro


Jin Zhang¹ · Ju-Fang Peng¹ · Yu-Bin Bai² · Ping Wang¹ · Tao Wang¹ · Jin-Ming Gao² · Zun-Ting Zhang¹

Received: 1 April 2016 / Accepted: 11 July 2016
© Springer International Publishing Switzerland 2016

Abstract 5,6-Diarylpyrazolo[1,5-*a*]pyrimidines (**3**) and 6,7-diarylpyrazolo[1,5-*a*]pyrimidines (**4**) were chemoselectively synthesized by the condensation of isoflavone (**1**) and 3-aminopyrazole (**2**). 5,6-Diarylpyrazolo[1,5-*a*]pyrimidines (**3**) were obtained via microwave irradiation, and 6,7-diarylpyrazolo[1,5-*a*]pyrimidines (**4**) were obtained *via* conventional heating. In addition, the pyrimidine derivatives **3** and **4** were evaluated against five phytopathogenic fungi (*Cytospora* sp., *Colletotrichum gloeosporioides*, *Botrytis cinerea*, *Alternaria solani*, and *Fusarium solani*) using the mycelium growth rate method. Some of them were effective in inhibiting the growth of the five phytopathogenic

fungi. For instance, 6,7-diarylpyrazolo[1,5-*a*]pyrimidines (**4j**) inhibited the growth of *A. solani* with an IC₅₀ value of 17.11 μg/mL, and 6,7-diarylpyrazolo[1,5-*a*]pyrimidines (**4h**) inhibited the growth of both *Cytospora* sp. and *F. solani* with IC₅₀ values of 27.32 and 21.04 μg/mL, respectively.

Graphical Abstract A chemoselective synthesis of 5,6-pyrazolo[1,5-*a*]pyrimidines **3** derivatives in excellent yields was performed under microwave irradiation and 6,7-pyrazolo[1,5-*a*]pyrimidines **4** were also prepared using heating method. The antifungal properties of **3** and **4** were tested against *Cytospora* sp., *Colletotrichum gloeosporioides*, *Botrytis cinerea*, *Alternaria solani*, and *Fusarium solani*.



Electronic supplementary material The online version of this article (doi:10.1007/s11030-016-9690-y) contains supplementary material, which is available to authorized users.

✉ Zun-Ting Zhang
zhangzt@snnu.edu.cn

¹ Key Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry, National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi'an 710062, People's Republic of China

Keywords Pyrazolo[1,5-*a*]pyrimidines · Chemoselectivity · Synthesized · Phytopathogenic fungi · Antifungal


² Shaanxi Engineering Center of Bioresource Chemistry and Sustainable Utilization, College of Science, Northwest A&F University, Yangling, 712100, People's Republic of China

Abbreviations


HRMS	High-resolution mass spectrometry
TLC	Thin-layer chromatography
mp	Melting point
IC ₅₀	Half-maximal inhibitory concentration
SAR	Structure–activity relationship
PDA	Potato dextrose agar

Introduction

Phytopathogenic fungi cause severe yield losses and quality decrease of crop production when they infect tissues at any growth stage of a plant [1]. Moreover, phytopathogenic fungi can produce mycotoxins that can be severely harmful to animal and human health [2]. As a result, scientists have developed a variety of different antifungal agents to control those fungi [3]. Although fungicides have played a vital role in preventing and treating this problem, several drawbacks, such as severe drug resistance, serious drug interactions, drug-related toxicity, and nonoptimal pharmacokinetics, still make the current antifungal agents far from ideal for antifungal therapy [4,5]. Therefore, new, safer, and more effective antifungal agents are still urgently needed.



Scheme 1 Examples of pyrazole-based fungicides



Scheme 2 General synthetic route for compounds 3 and 4

Pyrazolo[1,5-*a*]pyrimidines have a wide range of biological and pharmaceutical activities, which have been patented for herbicide, insecticide, and sterilization uses [6]. They have also been reported to be antitrichomonal agents and effectively inhibit trichophyton mentagrophytes [7,8]. In addition, they are also known to act as HIV reverse transcriptase inhibitors [9] and antifungal agents [10]. Pyrazole antifungals such as pyraclostrobin and furametpyr (Scheme 1a, b) were used to control plant fungi. Among them, pyraclostrobin showed a broad spectrum of antifungal activities because it is a strobilurin-mitochondrial electron transport inhibitor [11]. Furametpyr was reported to control rice sheath blight, which was caused by *Rhizoctonia solani* [12]. Moreover, a large number of polycyclic pyrazole fungicides have also been synthesized. For example, pyrazolo[3,4-*d*]pyrimidine-4(5*H*)-thiones and 2-methyl-*N*-phenylpyrazolo[1,5-*a*]pyrimidine-3-carboxamide (Scheme 1c, d) exhibited remarkable inhibition activities against *Rhizoctonia solani* and *Pythium ultimum* [13,14]. Pyrazolo[1,5-*c*][1,3,5]thiadiazin-4-one/thione and pyrazolo[3,4-*d*][1,3]thiazin-4-one/thione derivatives (Scheme 1e, f) were tested for antifungal activity against *Magnaporthe grisea* to control rice blast disease, and some of these compounds effectively inhibited fungal growth [15].

Based on pyrazolo[1,5-*a*]pyrimidines' broad spectrum of pharmacological and medicinal properties, several synthesis of pyrazolo[1,5-*a*]pyrimidines have been reported. Among such approaches, the most common one is the condensation of aminopyrazoles with 1,3-bis-electrophilic compounds (i.e., α, β -unsaturated carbonyl compounds) [16,17]. In our previous work, 6,7-diarylpyrazolo[1,5-*a*]pyrimidines **4** were synthesized by the condensation of isoflavone **1** and 3-aminopyrazole **2** under conventional heating (Scheme 2) [18]. However, this approach suffered from a long reaction time and low yields. In order to address these limitations, microwave irradiation was used instead [19–21]. Surprisingly, unexpected 5,6-diarylpyrazolo[1,5-*a*]pyrimidine





Fig. 1 Crystal structure of **3a**

Table 1 Optimization of cyclocondensation of isoflavone **1a** with 3-aminopyrazole **2**



Entry	Solvent	Base	Molar ratios 1a/2/base	T (°C)	3a yield (%) ^a
1	CH ₃ OH	CH ₃ ONa	1:2:2.5	68	27
2	CH ₃ OH	K ₂ CO ₃	1:2:2.5	68	0
3	CH ₃ OH	NaOH	1:2:2.5	68	20
4	CH ₃ OH	(CH ₃) ₃ COK	1:2:2.5	68	65
5	CH ₃ CH ₂ OH	(CH ₃) ₃ COK	1:2:2.5	79	63
6	DMSO	(CH ₃) ₃ COK	1:2:2.5	120	81
7	DMSO	(CH ₃) ₃ COK	1:1:2.5	120	70
8	DMSO	(CH ₃) ₃ COK	1:1.5:2.5	120	83
9	DMSO	(CH ₃) ₃ COK	1:1.5:2	120	63
10	DMSO	(CH ₃) ₃ COK	1:1.5:3	120	67
11	DMSO	(CH ₃) ₃ COK	1:1.5:2.5	100	82 ^b
12	DMSO	(CH ₃) ₃ COK	1:1.5:2.5	90	72

All reactions were carried out on 1 mmol scale of **1a** in 20 mL of solvent

^a Isolated yield on the basis of isoflavone **1a**

^b Microwave irradiation for 10 min; yield of **3a** was 65 %

derivatives **3** were obtained with high chemoselectivity (Scheme 2). We herein report the preparation of derivatives **3** and **4** and their antifungal activities.


Results and discussion

Chemistry

In order to improve the formation of 6,7-diarylpirazolo[1,5-*a*]pyrimidine **4a**, MeONa (2.5 mmol) was added as a base for the condensation of 7-isopropoxyisoflavone (**1a**; 1 mmol) and 3-aminopyrazole (**2a**; 1.5 mmol) in methanol (20 mL) under microwave irradiation. To our surprise, 5,6-diarylpirazolo[1,5-*a*]pyrimidine **3a** was obtained instead (confirmed by single-crystal X-ray diffraction analysis) (Fig. 1).

Optimization of the reaction conditions for the preparation of **3a** is shown in Table 1. Different bases were tested and it was found that (CH₃)₃COK was the best choice (entry 4). Further investigation on solvents (entries 4–6) and equivalents of reactants (entries 6–11) revealed that DMSO provided the best results when the equivalent ratio of reactants was 1:1.5:2.5 (**1a**: **2a**: (CH₃)₃COK; entry 8).

Under our optimized conditions, a variety of 5,6-diarylpirazolo[1,5-*a*]pyrimidines **3a–3t** were synthesized

Table 2 Synthesized **3** and **4** analogs

Reaction times for the preparation of **4a-4k** were 16–54 h. Isolated yield after column chromatography

from isoflavones **1** and 3-aminopyrazoles **2** (Table 2). 6,7-Diarylpyrazolo[1,5-*a*]pyrimidine derivatives (**4a–4i**) were prepared using our conventional heating method (Table 2) [19]. While these results show the importance of the heating source, the reason for the observed chemoselectivity is not clear. As a general trend, substrates bearing electron-donating groups afforded the corresponding products in higher yields than those with electron-withdrawing groups.

Antifungal activity

Twenty 5,6-diarylpyrazolo[1,5-*a*]pyrimidines (**3a–3t**) and eleven 6,7-diarylpyrazolo[1,5-*a*] pyrimidines (**4a–4k**) were screened at 50 $\mu\text{g/mL}$ primarily to determine their antifungal performance against *Cytospora* sp., *Colletotrichum gloeosporioides*, *Botrytis cinerea*, *Alternaria solani*, and *Fusarium solani* (Table 3). The mycelial growth inhibition rates of compounds **3f**, **3p**, **4a**, **4h**, **4j**, and **4k** were over 60 % and they were selected to obtain their IC_{50} values (Table 4) [22].

As shown in Table 4, compounds **3f**, **3p**, **4a**, **4h**, **4j**, and **4k** exhibited different antifungal activities against the five tested fungi. These analogs performed better than the positive control hymexazol against *Cytospora* sp., *C. gloeosporioides*, *A. solani*, and *F. Solani*; however, they were almost inactive to *Botrytis cinerea* compared to hymexazol ($\text{IC}_{50} = 7.23 \pm 0.33 \mu\text{g/mL}$). Of special interest was that analog **4** exhibited better antifungal activity than **3**. Analog **4a** and **4k** exhibited IC_{50} values of 19–33 $\mu\text{g/mL}$ against *Cytospora* sp., *C. gloeosporioides*, *A. solani*, and *F. Solani*.

When the 4'-isopropoxy on the 7-phenyl group of **4a** and the 5'-fluoro on the 7-phenyl group of **4k** were included, their antifungal activities and broad-spectrum antifungal properties were enhanced. Compound **4h**, bearing a 4'-methoxy group on the 6-phenyl group, showed higher growth inhibition against *Cytospora* sp. and *F. Solani* ($\text{IC}_{50} = 27.32 \pm 0.31 \mu\text{g/mL}$ and $21.40 \pm 0.37 \mu\text{g/mL}$, respectively). Notably, **4j** with a 4'-trifluoromethyl unit on the 6-phenyl group had a significant effect toward inhibiting *A. solani* ($\text{IC}_{50} = 17.11 \pm 0.41 \mu\text{g/mL}$) proving to be much better than the control hymexazol ($\text{IC}_{50} > 50 \mu\text{g/mL}$). Similarly, **4k**, having a 4'-trifluoromethyl group, was also effective against *A. solani* ($\text{IC}_{50} = 20.64 \pm 1.05 \mu\text{g/mL}$). These results indicate that the trifluoromethyl group of **4** could be a key group necessary to inhibit the growth of *A. solani*.

In the case of 5,6-diarylpyrazolo[1,5-*a*]pyrimidines, compound **3f** showed antifungal activity against *Cytospora* sp. with an IC_{50} of $44.83 \pm 0.53 \mu\text{g/mL}$, and **3p** against *C. gloeosporioides* and *F. Solani* with an IC_{50} of $57.61 \pm 1.74 \mu\text{g/mL}$ and $35.21 \pm 3.76 \mu\text{g/mL}$, respectively.

Table 3 Preliminary antifungal activity of compounds **3** and **4** at 50 $\mu\text{g/mL}$

Entry	Compd.	Average antifungal rate (%)				
		C.s.	C.g.	B.c.	A.s.	F.s.
1	3a	0.41	5.30	15.64	0.62	3.49
2	3b	0.82	17.42	26.38	4.32	2.82
3	3c	40.82	44.70	30.98	23.46	40.35
4	3d	6.12	24.24	23.31	6.17	20.91
5	3e	48.98	57.58	41.72	45.06	37.67
6	3f	59.85	54.59	38.65	34.57	46.38
7	3g	0.41	0.61	15.64	0.25	0.27
8	3h	6.63	13.64	11.04	10.49	14.21
9	3i	47.96	51.52	41.72	54.32	54.42
10	3j	36.73	53.03	35.58	32.10	39.68
11	3k	4.59	6.82	11.04	0.49	3.49
12	3l	26.53	25.76	23.31	19.75	22.25
13	3m	0.00	5.30	27.91	0.74	4.16
14	3n	34.18	40.91	35.58	27.78	25.60
15	3o	1.02	8.33	21.78	0.00	3.49
16	3p	50.00	59.09	35.58	49.38	63.81
17	3q	26.53	30.30	23.31	17.28	28.95
18	3r	1.53	22.73	11.04	2.47	0.54
19	3s	4.08	18.18	11.04	7.41	22.25
20	3t	51.02	50.76	32.52	41.98	49.73
21	4a	54.72	60.61	35.58	70.37	71.85
22	4b	51.61	52.46	14.00	45.27	41.55
23	4c	32.65	33.33	29.45	38.27	55.76
24	4d	51.61	56.56	12.00	56.08	45.07
25	4e	52.69	39.34	8.00	51.35	39.44
26	4f	26.34	36.89	8.00	33.78	14.08
27	4g	29.57	21.31	4.00	18.24	15.49
28	4h	72.45	43.94	35.58	46.91	85.25
29	4i	22.58	42.62	44.00	19.59	20.42
30	4j	56.45	66.39	30.00	69.59	48.59
31	4k	70.43	68.03	40.00	72.97	75.35
32	Hy	23.74	18.18	100.00	56.37	42.36

A. s., *Alternaria solani*; B. c., *Botrytis cinerea*; C. g., *Colletotrichum gloeosporioides*; C. s. *Cytospora* sp.; F. s., *Fusarium solani*; Hy, hymexazol

Conclusions

In summary, we report the chemoselective synthesis of 5,6-pyrazolo[1,5-*a*]pyrimidine (**3a–3t**) derivatives in excellent yields under microwave irradiation. Pyrazolo[1,5-*a*]pyrimidines **4** were also selectively prepared using conventional heating. The antifungal profiles of compounds **3** and **4** against *Cytospora* sp., *C. gloeosporioides*, *Alternaria solani*, and *F. Solani* were obtained. Among these analogs, **4h** exhibited higher inhibition toward fungi *Cytospora* sp. and *F. Solani* ($\text{IC}_{50} = 27.32 \pm 0.31 \mu\text{g/mL}$ and

Table 4 Antifungal activity of selected compounds

Compd	IC ₅₀ ± SD/(μg/mL)				
	C.s.	C.g.	B.c.	A.s.	F.s.
3f	44.83 ± 0.53	>50	>100	>100	>50
3p	>50	57.61 ± 1.74	>50	>50	35.21 ± 3.76
4a	27.08 ± 0.72	21.99 ± 0.22	>50	21.12 ± 0.64	28.59 ± 0.95
4h	27.32 ± 0.31	>50	>50	>50	21.40 ± 0.37
4j	>50	40.71 ± 0.64	>50	17.11 ± 0.41	>50
4k	25.22 ± 0.93	33.56 ± 1.41	>50	20.64 ± 1.05	19.54 ± 0.37
Hy	>100	>100	7.23 ± 0.33	52.38 ± 4.38	38.45 ± 2.50

21.40 ± 0.37 μg/mL, respectively), **4j** had strong antifungal activity toward *Alternaria solani* (IC₅₀ = 17.11 ± 0.41 μg/mL), and they all perform better than fungicide hymexazol. Compounds **4a**, **4h**, **4j**, and **4k** offer a great opportunity as starting points for further optimization toward improved antifungal agrochemicals.

Experimental procedures

Instruments

Microwave irradiation was carried out using the commercial microwave oven MCR-3 (Gongyi Yuhua Instrument Corp. Ltd., China). Melting points were measured using X-5 melting point apparatus and were uncorrected. ¹H NMR and ¹³C NMR spectra were recorded on a Bruker AM 400 or 600 instrument using either CDCl₃ or DMSO-*d*₆ as a deuterated solvent. Chemical shifts are given in δ relative to tetramethylsilane (TMS) as an internal standard, and coupling constants *J* are given in Hz. Abbreviations used for ¹H NMR signals are *s* = singlet, *d* = doublet, *m* = multiplet, *b* = broad, and *dd* = doublet of doublet. High-resolution mass spectrometry (HRMS) was performed on a Bruker Maxis instrument using electrospray ionization quadrupole time-of-flight (ESI-Q-TOF) technique and IR spectra were recorded on a Nicolet 170SX FT-IR spectrophotometer with KBr pellets. The crystal diffraction data were collected on a Bruker Smart-1000 CCD diffractometer. Thin-layer chromatography (TLC) used silica gel 60 GF254 plate. Silica gel (size 200–300 mesh) used for column chromatography was purchased from Qingdao Haiyang Chemistry Plant (China). All starting materials were obtained from commercial sources and used without purification.

Fungal material

Five species of fungi *Cytospora* sp., *Colletotrichum gloeosporioides*, *Botrytis cinerea*, *Alternaria solani*, and *Fusarium solani* were all kindly provided by the Institute of Pesticides, Northwest A&F University. The method used for culturing them was general fungi culture technique, i.e., inoculating

and culturing on PDA (potato dextrose agar) at 28 °C for 5–7 days.

General procedure for the synthesis of 5,6-diarylpyridine[1,5-*a*]pyrimidines (**3a–3t**)

The corresponding isoflavone (**1**; 1 mmol), 3-aminopyrazole (**2a**; 1.5 mmol) or 3-amino-5-methylpyrazole (**2b**; 1.5 mmol), and (CH₃)₃COK (280 mg, 2.5 mmol) were dissolved in 20 mL of anhydrous DMSO (20 mL), and the solution was subsequently stirred and irradiated under microwave irradiation for 15 min. Then, the reaction mixture was poured onto brine (100 mL) and adjusted to pH 6–7 by the addition of 20 % HCl. The resulting yellow precipitate was filtered and purified via column chromatography on silica gel (petroleum ether) to give **3** in moderate to good yields.

5-(2-Hydroxy-4-isopropoxyphenyl)-6-phenylpyrazolo[1,5-*a*]pyrimidine (**3a**)

Yellow solid; mp, 162.3–163.4 °C; IR (KBr) ν (cm⁻¹) 3545, 3513, 3420, 2024, 1620, 1390, 1178, 826, 612; ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) 9.70 (s, 1H), 9.04 (s, 1H), 8.24 (d, *J* = 2.4 Hz, 1H), 7.28 (s, 5H), 7.09 (d, *J* = 8.4 Hz, 1H), 6.72 (d, *J* = 2.0 Hz, 1H), 6.36 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.23 (d, *J* = 2.0 Hz, 1H), 4.51 (m, 1H), 1.24 (m, 6H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ (ppm) 159.1, 157.2, 156.3, 146.5, 145.0, 136.1, 133.9, 131.3, 129.0, 127.7, 127.1, 123.5, 118.3, 106.1, 102.5, 95.9, 69.1, 21.7. HRMS (ESI): *m/z* [M+H]⁺ calculated for C₂₁H₂₀N₃O₂: 368.1375; found: 368.1365.

5-(2-Hydroxy-4-methoxyphenyl)-6-phenylpyrazolo[1,5-*a*]pyrimidine (**3b**)

Yellow solid; mp, 192.5–195.7 °C; IR (KBr) ν (cm⁻¹) 3559, 3423, 3239, 2961, 2029, 1618, 1486, 1409, 1238, 1139, 819, 632; ¹H NMR (600 MHz, DMSO-*d*₆) δ (ppm) 9.72 (s, 1H), 9.02 (s, 1H), 8.22 (s, 1H), 7.26 (s, 5H), 7.10 (d, *J* = 8.4 Hz, 1H), 6.71 (s, 1H), 6.37 (d, *J* = 8.4 Hz, 1H), 6.24 (s, 1H), 3.67 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ (ppm) 161.4, 157.5, 156.6, 147.0, 145.7, 136.7, 134.7, 131.8, 129.0, 128.5,

127.8, 123.9, 119.0, 105.2, 101.5, 96.1, 55.5. HRMS (ESI): m/z $[M+H]^+$ calculated for $C_{19}H_{16}N_3O_2$: 340.1062; found: 340.1048.

5-(2-Hydroxy-4-methoxy)phenyl-6-(4-methyl)phenylpyrazolo[1,5-*a*]pyrimidine (**3c**)

Yellow solid; mp, 178.5–180.2 °C; IR (KBr) ν (cm^{-1}) 3557, 3478, 3417, 3238, 2959, 2026, 1620, 1388, 1240, 1108, 838, 629; 1H NMR (600 MHz, DMSO- d_6) δ (ppm) 9.74 (s, 1H), 8.98 (s, 1H), 8.23 (d, $J = 2.4$ Hz, 1H), 7.16 (m, 2H), 7.11 (m, 3H), 6.71 (d, $J = 1.8$ Hz, 1H), 6.40 (dd, $J = 8.4, 1.8$ Hz, 1H), 6.27 (d, $J = 1.8$ Hz, 1H), 3.71 (m, 3H), 2.28 (m, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ (ppm) 160.9, 157.0, 156.1, 146.3, 145.1, 136.5, 134.0, 133.3, 131.3, 130.0, 128.8, 128.64, 123.4, 118.6, 113.6, 104.7, 101.0, 95.5, 55.0, 20.6. HRMS (ESI): m/z $[M+Na]^+$ calculated for $C_{20}H_{17}N_3O_2Na$: 354.1218; found: 354.1218.

5-(2-Hydroxy-4-methoxy)phenyl-6-(4-methoxy)phenylpyrazolo[1,5-*a*]pyrimidine (**3d**)

Yellow solid; mp, 176.4–180.2 °C; IR (KBr) ν (cm^{-1}) 3566, 3512, 3430, 2836, 2026, 1615, 1384, 1242, 1117, 1029, 959, 816, 634; 1H NMR (600 MHz, DMSO- d_6) δ (ppm) 9.76 (s, 1H), 8.97 (s, 1H), 8.22 (d, $J = 2.4$ Hz, 1H), 7.19 (m, 2H), 7.11 (d, $J = 9.0$ Hz, 1H), 6.86 (d, $J = 9.0$ Hz, 1H), 6.70 (d, $J = 2.4$ Hz, 1H), 6.40 (dd, $J = 8.4, 2.4$ Hz, 1H), 6.29 (m, 1H), 3.74 (m, 3H), 3.73 (m, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ (ppm) 160.8, 158.5, 157.1, 156.2, 146.3, 145.0, 133.8, 131.3, 130.1, 128.3, 123.1, 118.5, 113.5, 104.7, 101.1, 95.4, 55.0, 55.0. HRMS (ESI): m/z $[M+Na]^+$ calculated for $C_{20}H_{17}N_3O_3Na$: 370.1168; found: 370.1148.

5-(2-Hydroxyphenyl)-6-phenylpyrazolo[1,5-*a*]pyrimidine (**3e**)

Yellow solid; mp, 146.6–149.3 °C; IR (KBr) ν (cm^{-1}) 3577, 3442, 3354, 3032, 2025, 1616, 1489, 1404, 1247, 1156, 1068, 751, 641; 1H NMR (400 MHz, DMSO- d_6) δ (ppm) 9.45 (s, 1H), 9.08 (s, 1H), 8.27 (d, $J = 2.4$ Hz, 1H), 7.26 (s, 5H), 7.23 (d, $J = 8.0$ Hz, 1H), 7.16 (m, 1H), 6.80 (m, 1H), 6.75 (s, 1H), 6.69 (d, $J = 8.0$ Hz, 1H); ^{13}C NMR (100 MHz, DMSO- d_6) δ (ppm) 157.2, 154.4, 146.6, 145.2, 135.8, 133.9, 130.3, 130.0, 129.0, 127.9, 127.3, 126.1, 123.5, 118.6, 115.5, 95.8. HRMS (ESI): m/z $[M+Na]^+$ calculated for $C_{18}H_{13}N_3ONa$: 310.0956; found: 310.0943.

5-(2-Hydroxyphenyl)-6-(4-methoxyphenyl)pyrazolo[1,5-*a*]pyrimidine (**3f**)

Yellow solid; mp, 166.2–169.3 °C; IR (KBr) ν (cm^{-1}) 3522, 3452, 3413, 2960, 2031, 1639, 1256, 1026, 808, 657; 1H

NMR (600 MHz, DMSO- d_6) δ (ppm) 9.45 (s, 1H), 9.02 (s, 1H), 8.24 (d, $J = 2.4$ Hz, 1H), 7.22 (d, $J = 7.8$ Hz, 1H), 7.18 (m, 3H), 6.82 (m, 3H), 6.73 (m, 2H), 3.72 (s, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ (ppm) 158.6, 157.4, 154.5, 146.5, 145.1, 133.6, 130.3, 130.2, 130.0, 128.0, 126.3, 123.3, 118.6, 115.5, 113.4, 95.7, 55.0. HRMS (ESI): m/z $[M+Na]^+$ calculated for $C_{19}H_{15}N_3O_2Na$: 340.1062; found: 340.1047.

5-(2-Hydroxy-4-methoxy)phenyl-6-(4-fluorine)phenylpyrazolo[1,5-*a*]pyrimidine (**3g**)

Yellow solid; mp, 158.3–162.5 °C; IR (KBr) ν (cm^{-1}) 3554, 3483, 3452, 2960, 2026, 1622, 1359, 1073, 823, 629; 1H NMR (600 MHz, DMSO- d_6) δ (ppm) 9.65 (s, 1H), 9.04 (s, 1H), 8.22 (d, $J = 2.4$ Hz, 1H), 7.27 (m, 2H), 7.12 (m, 3H), 6.70 (d, $J = 1.8$ Hz, 1H), 6.40 (dd, $J = 8.4, 2.4$ Hz, 1H), 6.23 (d, $J = 1.8$ Hz, 1H), 3.68 (m, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ (ppm) 162.01 ($^1J = 243$ Hz), 161.5, 157.5, 156.4, 147.1, 145.8, 134.6, 133.1, 133.1, 131.9, 131.5 ($^3J = 8.4$ Hz), 123.0, 119.0, 115.3 ($^2J = 21.6$ Hz), 105.3, 101.4, 96.1, 55.5. HRMS (ESI): m/z $[M+Na]^+$ calculated for $C_{19}H_{14}FN_3O_2Na$: 358.0968; found: 358.0946.

5-(2-Hydroxy-4-methoxy)phenyl-6-(4-trifluoromethyl)phenylpyrazolo[1,5-*a*]pyrimidine (**3h**)

Yellow solid; mp, 165.2–167.1 °C; IR (KBr) ν (cm^{-1}) 3568, 3502, 3439, 3235, 2945, 2026, 1618, 1480, 1407, 1327, 1282, 1155, 1109, 1065, 843, 641; 1H NMR [600 MHz, DMSO- d_6] δ (ppm) 9.60 (s, 1H), 9.16 (s, 1H), 8.28 (d, $J = 2.4$ Hz, 1H), 7.67 (m, 2H), 7.49 (m, 2H), 7.26 (d, $J = 8.4$ Hz, 1H), 6.76 (d, $J = 2.4$ Hz, 1H), 6.47 (dd, $J = 8.4, 2.4$ Hz, 1H), 6.23 (d, $J = 2.4$ Hz, 1H), 3.71 (m, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ (ppm) 161.2, 156.5, 155.7, 146.8, 145.6, 140.7, 134.6, 131.5, 129.6, 127.6 ($^2J = 31.35$ Hz), 124.7 ($^3J = 3.45$ Hz), 124.3 ($^1J = 270.3$ Hz), 122.2, 118.4, 105.0, 100.9, 95.8, 55.0. HRMS (ESI): m/z $[M+Na]^+$ calculated for $C_{20}H_{14}F_3N_3O_2Na$: 408.0936; found: 408.0920.

5-(2-Hydroxy-5-fluorine)phenyl-6-phenylpyrazolo[1,5-*a*]pyrimidine (**3i**)

Yellow solid; mp, 154.6–157.4 °C; IR (KBr) ν (cm^{-1}) 3567, 3501, 3439, 3235, 2960, 2026, 1618, 1493, 1412, 1248, 1172, 1074, 974, 902, 831, 635; 1H NMR (400 MHz, DMSO- d_6) δ (ppm) 9.43 (s, 1H), 9.12 (s, 1H), 8.28 (d, $J = 2.4$ Hz, 1H), 7.29 (s, 5H), 7.11 (d, $J = 8.4$ Hz, 1H), 7.01 (m, 1H), 6.77 (s, 1H), 6.67 (m, 1H); ^{13}C NMR (100 MHz, DMSO- d_6) δ (ppm) 155.9, 154.9 ($^1J = 233$ Hz), 150.8, 146.6, 145.4, 135.5, 134.1, 129.1, 127.9, 127.4, 127.0 ($^3J = 7.6$ Hz), 123.4, 116.4 ($^2J = 23.7$ Hz), 116.4 ($^2J = 21.9$ Hz), 116.5 ($^3J = 8.5$ Hz), 96.0. HRMS (ESI): m/z $[M+Na]^+$ calculated for $C_{18}H_{12}FN_3ONa$: 328.0862; found: 328.0845.

5-(2-Hydroxy-5-fluorine)phenyl-6-(4-methoxy)phenylpyrazolo[1,5-a]pyrimidine (**3j**)

Yellow solid; mp, 150.8–153.7 °C; IR (KBr) ν (cm⁻¹) 3581, 3511, 3446, 3380, 2960, 2071, 1641, 1489, 1252, 1024, 845, 662; ¹H NMR (600 MHz, DMSO-*d*₆) δ (ppm) 9.43 (s, 1H), 9.06 (s, 1H), 8.26 (d, *J* = 2.4 Hz, 1H), 7.21 (m, 2H), 7.11 (dd, *J* = 8.4, 2.4 Hz, 1H), 7.03 (m, 1H), 6.85 (m, 2H), 6.76 (d, *J* = 2.4 Hz, 1H), 6.69 (dd, *J* = 8.4, 2.4 Hz, 1H), 3.73 (m, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ (ppm) 158.6, 156.1, 154.9 (¹*J* = 233.0 Hz), 150.8, 146.4, 145.2, 133.7, 130.3, 127.7, 127.2 (³*J* = 7.5 Hz), 123.2, 116.5 (³*J* = 233.0 Hz), 116.4 (²*J* = 233.0 Hz), 116.3 (²*J* = 22.7 Hz), 113.4, 95.9, 55.0. HRMS (ESI): *m/z* [M+Na]⁺ calculated for C₁₉H₁₄FN₃O₂Na: 358.0968; found: 358.0952.

2-Methyl-5-(2-hydroxy-4-isopropoxy)phenyl-6-phenylpyrazolo[1,5-a]pyrimidine (**3k**)

Yellow solid; mp, 154.5–155.1 °C; IR (KBr) ν (cm⁻¹) 3570, 3512, 3423, 2026, 1618, 1420, 1294, 1198, 1155, 804, 602; ¹H NMR (600 MHz, DMSO-*d*₆) δ (ppm) 9.79 (s, 1H), 8.90 (s, 1H), 7.27 (m, 5H), 7.05 (d, *J* = 8.4 Hz, 1H), 6.50 (s, 1H), 6.34 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.24 (d, *J* = 2.4 Hz, 1H), 4.51 (m, 1H), 2.45 (s, 3H), 1.24 (s, 3H), 1.23 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ (ppm) 159.1, 156.5, 156.3, 154.7, 147.1, 136.4, 133.7, 131.3, 128.9, 128.0, 127.1, 122.4, 118.0, 106.2, 102.6, 94.6, 69.1, 21.7, 14.3. HRMS (ESI): *m/z* [M+Na]⁺ calculated for C₂₂H₂₁N₃O₂Na: 382.1531; found: 382.1512.

2-Methyl-5-(2-hydroxy-4-methoxy)phenyl-6-(4-methoxy)phenylpyrazolo[1,5-a]pyrimidine (**3l**)

Yellow solid; mp, 208.7–210.9 °C; IR (KBr) ν (cm⁻¹) 3557, 3483, 3438, 2961, 2027, 1619, 1387, 1281, 1127, 1074, 827, 634; ¹H NMR (600 MHz, DMSO-*d*₆) δ (ppm) 9.83 (s, 2H), 8.84 (s, 2H), 7.16 (m, 2H), 7.08 (m, 2H), 6.85 (m, 2H), 6.48 (br, 1H), 6.38 (dd, *J* = 8.4, 2.2 Hz, 1H), 6.28 (m, 2H), 3.74 (s, 3H), 3.70 (s, 3H), 2.45 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ (ppm) 160.8, 158.5, 156.6, 156.2, 154.5, 147.0, 133.4, 131.3, 130.1, 128.5, 122.2, 118.4, 113.5, 104.7, 101.1, 94.5, 55.0, 55.0, 14.2. HRMS (ESI): *m/z* [M+Na]⁺ calculated for C₂₁H₁₉N₃O₃Na: 384.1324; found: 384.1307.

2-Methyl-5-(2-hydroxy-4-methoxy)phenyl-6-(4-methyl)phenylpyrazolo[1,5-a]pyrimidine (**3m**)

Yellow solid; mp, 208.4–211.2 °C; IR (KBr) ν (cm⁻¹) 3564, 3440, 3233, 2960, 2025, 1620, 1389, 1123, 823, 634; ¹H NMR (600 MHz, DMSO-*d*₆) δ (ppm) 9.80 (s, 1H), 8.85 (s, 1H), 7.14 (m, 2H), 7.09 (m, 3H), 6.49 (br, 1H), 6.37 (dd, *J* = 8.4, 2.2 Hz, 1H), 6.27 (d, *J* = 2.4 Hz, 1H), 3.70 (s, 3H), 2.45 (s, 3H), 2.28 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆)

δ (ppm) 160.8, 156.5, 156.2, 154.6, 147.0, 136.3, 133.49, 133.4, 131.3, 128.8, 128.7, 122.4, 118.5, 104.6, 101.0, 94.6, 55.0, 20.6, 14.3; HRMS (ESI): *m/z* [M+Na]⁺ calculated for C₂₁H₁₉N₃O₂Na: 368.1375; found: 368.1359.

2-Methyl-5-(2-hydroxy)phenyl-6-phenylpyrazolo[1,5-a]pyrimidine (**3n**)

Yellow solid; mp, 158.2–159.7 °C; IR (KBr) ν (cm⁻¹) 3453, 3420, 2956, 2027, 1621, 1393, 1075, 849, 631; ¹H NMR (600 MHz, DMSO-*d*₆) δ (ppm) 9.45 (s, 1H), 8.95 (s, 1H), 7.25 (s, 5H), 7.20 (d, *J* = 7.8 Hz, 1H), 7.16 (m, 1H), 6.80 (m, 1H), 6.69 (d, *J* = 7.8 Hz, 1H), 6.53 (br, 1H), 2.47 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ (ppm) 156.8, 154.7, 154.5, 147.3, 136.0, 133.4, 130.3, 129.9, 129.0, 127.9, 127.1, 126.1, 122.7, 118.6, 115.5, 94.9, 14.3. HRMS (ESI): *m/z* [M+Na]⁺ calculated for C₁₉H₁₅N₃O₂Na: 324.1113; found: 324.1098.

2-Methyl-5-(2-hydroxy)phenyl-6-(4-methoxy)phenylpyrazolo[1,5-a]pyrimidine (**3o**)

Yellow solid; mp, 208.8–210.0 °C; IR (KBr) ν (cm⁻¹) 3440, 3383, 2961, 2027, 1620, 1395, 1075, 829, 629; ¹H NMR (600 MHz, DMSO-*d*₆) δ (ppm) 9.44 (s, 1H), 8.89 (s, 1H), 7.19–7.15 (m, 4H), 6.80 (m, 3H), 6.72 (d, *J* = 7.8 Hz, 1H), 6.5 (br, 1H), 3.72 (s, 3H), 2.46 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ (ppm) 158.5, 156.9, 154.5, 154.5, 147.2, 133.1, 130.3, 130.1, 129.9, 128.2, 126.3, 122.4, 118.6, 115.5, 113.4, 94.8, 55.0, 14.3. HRMS (ESI): *m/z* [M+Na]⁺ calculated for C₂₀H₁₇N₃O₂Na: 354.1218; found: 354.1201.

2-Methyl-5-(2-hydroxy)phenyl-6-(4-trifluoromethyl)phenylpyrazolo[1,5-a]pyrimidine (**3p**)

Yellow solid; mp, 215.3–217.5 °C; IR (KBr) ν (cm⁻¹) 3484, 3240, 2960, 2028, 1624, 1391, 1326, 1121, 840, 627; ¹H NMR (600 MHz, DMSO-*d*₆) δ (ppm) 9.43 (s, 1H), 9.07 (s, 1H), 7.62 (m, 2H), 7.46 (m, 2H), 7.31 (d, *J* = 7.8 Hz, 1H), 7.19 (m, 1H), 6.86 (m, 1H), 6.67 (d, *J* = 7.8 Hz, 1H), 6.57 (br, 1H), 2.48 (s, 3H); ¹³C NMR (150 MHz, DMSO-*d*₆) δ (ppm) 156.3, 155.2, 154.3, 147.5, 140.5, 133.9, 131.7, 130.5, 129.7, 127.6 (²*J* = 33.25 Hz), 125.9 (¹*J* = 217.65 Hz), 125.8, 124.6 (³*J* = 3.75 Hz), 121.4, 118.9, 115.5, 95.2, 14.3. HRMS (ESI): *m/z* [M+Na]⁺ calculated for C₂₀H₁₄F₃N₃O₂Na: 392.0987; found: 392.0968.

2-Methyl-5-(2-hydroxy-4-methoxy)phenyl-6-(4-fluorine)phenylpyrazolo[1,5-a]pyrimidine (**3q**)

Yellow solid; mp, 160.2–165.4 °C; IR (KBr) ν (cm⁻¹) 3489, 3415, 2960, 2027, 1620, 1388, 1078, 828, 630; ¹H NMR (600 MHz, DMSO-*d*₆) δ (ppm) 9.73 (s, 1H), 8.91 (s, 1H), 7.27 (m, 2H), 7.12 (m, 3H), 6.50 (s, 1H), 6.40 (m, 1H), 6.26

(s, 1H), 3.70 (s, 3H), 2.45 (s, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ (ppm) 161.5 ($^1J = 241.5$ Hz), 160.9, 156.5, 156.0, 154.7, 147.2, 133.6, 132.8, 131.4, 130.9 ($^3J = 7.8$ Hz), 121.6, 118.4, 114.8 ($^2J = 21.15$ Hz), 104.8, 101.0, 94.7, 55.0, 14.2. HRMS (ESI): m/z [M+Na] $^+$ calculated for $\text{C}_{20}\text{H}_{16}\text{FN}_3\text{O}_2\text{Na}$: 372.1124; found: 372.1105.

2-Methyl-5-(2-hydroxy-5-fluorine)phenyl-6-phenylpyrazolo[1,5-a]pyrimidine (3r)

Yellow solid; mp, 185.3–187.0 °C; IR (KBr) ν (cm^{-1}) 3487, 3378, 2960, 2026, 1622, 1491, 1395, 1275, 1073, 834, 629; ^1H NMR (600 MHz, DMSO- d_6) δ (ppm) 9.42 (s, 1H), 8.99 (s, 1H), 7.27 (s, 5H), 7.08 (dd, $J = 8.4, 2.4$ Hz, 1H), 7.00 (m, 1H), 6.67 (dd, $J = 8.4, 2.4$ Hz, 1H), 6.56 (s, 1H), 2.47 (s, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ (ppm) 155.4, 154.9, 154.8 ($^1J = 233$ Hz), 150.8, 147.2, 135.7, 133.5, 129.0, 127.9, 127.3, 127.1 ($^3J = 7.8$ Hz), 122.6, 116.4 ($^3J = 8.1$ Hz), 116.4 ($^2J = 23.3$ Hz), 116.3 ($^2J = 22.7$ Hz), 95.1, 14.3. HRMS (ESI): m/z [M+Na] $^+$ calculated for $\text{C}_{19}\text{H}_{14}\text{FN}_3\text{ONa}$: 342.1019; found: 342.1001.

2-Methyl-5-(2-hydroxy-5-fluorine)phenyl-6-(4-methoxy)phenylpyrazolo[1,5-a]pyrimidine (3s)

Yellow solid; mp, 171.2–173.4 °C; IR (KBr) ν (cm^{-1}) 3574, 3442, 3378, 2961, 1620, 1498, 1385, 1241, 1170, 828, 637; ^1H NMR (600 MHz, DMSO- d_6) δ (ppm) 9.43 (s, 1H), 8.92 (s, 1H), 7.18 (d, $J = 8.4$ Hz, 2H), 7.07 (dd, $J = 8.4, 2.4$ Hz, 1H), 7.01 (m, 1H), 6.84 (m, 2H), 6.69 (dd, $J = 8.4, 2.4$ Hz, 1H), 6.53 (s, 1H), 3.73 (s, 3H), 2.46 (s, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ (ppm) 158.6, 155.6, 154.9 ($^1J = 233.0$ Hz), 154.7, 150.8, 147.1, 133.2, 131.6 ($^2J = 33.9$ Hz), 130.2, 128.6, 127.9, 127.2 ($^3J = 7.5$ Hz), 122.3, 116.5 ($^3J = 7.2$ Hz), 116.2 ($^2J = 22.1$ Hz), 113.4, 94.9, 55.0, 14.2. HRMS (ESI): m/z [M+Na] $^+$ calculated for $\text{C}_{20}\text{H}_{16}\text{FN}_3\text{O}_2\text{Na}$: 372.1124; found: 372.1111.

2-Methyl-5-(2-hydroxy-5-fluorine)phenyl-6-(4-trifluoromethyl)phenylpyrazolo[1,5-a]pyrimidine (3t)

Yellow solid; mp, 193.8–195.4 °C; IR (KBr) ν (cm^{-1}) 3581, 3442, 3345, 3234, 2936, 2026, 1618, 1498, 1327, 1274, 1126, 1067, 834, 626; ^1H NMR (600 MHz, DMSO- d_6) δ (ppm) 9.43 (s, 1H), 9.10 (s, 1H), 7.65 (m, 2H), 7.49 (m, 2H), 7.20 (dd, $J = 8.4, 2.4$ Hz, 1H), 7.04 (m, 1H), 6.65 (dd, $J = 8.4, 2.4$ Hz, 1H), 6.59 (s, 1H), 2.48 (s, 3H); ^{13}C NMR (150 MHz, DMSO- d_6) δ (ppm) 155.3, 155.0 ($^1J = 233.1$ Hz), 155.0, 150.6, 147.4, 140.2, 134.0, 129.7, 127.9, 127.6, 126.6 ($^3J = 7.7$ Hz), 124.7, 124.2 ($^1J = 270.5$ Hz), 121.3, 116.7 ($^2J = 23.0$ Hz), 116.6 ($^2J = 24.5$ Hz), 116.4 ($^3J = 8.3$ Hz), 95.4, 14.4. HRMS (ESI): m/z [M+H] $^+$ calculated for $\text{C}_{20}\text{H}_{14}\text{N}_3\text{O}$: 388.1073; found: 388.1061.

General procedure for the synthesis of 6,7-diarylpyridine[1,5-a]pyrimidines (4a–4k)

4a–4k were prepared according to the literature [19]. The corresponding isoflavone (**1**; 1 mmol), 3-aminopyrazole (**2a**; 1.3 mmol) or 3-amino-5-methylpyrazole (**2b**; 1.3 mmol), and $(\text{CH}_3)_3\text{COK}$ (280 mg, 2 mmol) were stirred and refluxed in dried MeOH (20 mL) at 68 °C for 16–54 h. All reactions were monitored by TLC until **1** was fully consumed. The reaction mixture was then poured onto ice water (100 mL) and adjusted to pH 6–7 by the addition of 20 % HCl. The resulting yellow precipitate was filtered and purified via column chromatography on silica gel (petroleum ether) to give products **4a–4k**. The analytical data for compounds **4a–4i** are in agreement with the literature [19].

2-Methyl-6-(4-trifluoromethyl)-7-(2-hydroxy)phenylpyrazolo[1,5-a]pyrimidine (4j)

Yellow solid; mp, >300 °C; IR (KBr) ν (cm^{-1}) 3068, 2927, 1600, 1515, 1456, 1397, 1323, 1282, 1163, 1121, 1062, 837, 747; ^1H NMR (400 MHz, DMSO- d_6) δ (ppm) 9.87 (s, 1H), 8.60 (s, 1H), 7.66 (m, 2H), 7.49 (m, 2H), 7.28 (m, 1H), 7.15 (d, $J = 7.6$ Hz, 1H), 6.89 (d, $J = 8.4$ Hz, 1H), 6.82 (m, 1H), 6.65 (s, 1H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, DMSO- d_6) δ (ppm) 155.8, 154.9, 150.2, 149.1, 142.8, 140.1, 132.2, 130.6, 129.1, 128.2 ($^2J = 31.90$ Hz), 125.5 ($^3J = 3.50$ Hz), 124.0 ($^1J = 270.90$ Hz), 120.5, 119.4, 118.0, 116.2, 96.2, 14.9. HRMS (ESI): m/z [M+H] $^+$ calculated for $\text{C}_{20}\text{H}_{15}\text{N}_3\text{O}$: 370.1167; found: 370.1163.

6-(4-trifluoromethyl)-7-(2-hydroxy-5-fluorine)phenylpyrazolo[1,5-a]pyrimidine (4k)

Yellow solid; mp, >300 °C; IR (KBr) ν (cm^{-1}) 3043, 1610, 1517, 1443, 1323, 1271, 1171, 1121, 1059, 1011, 845, 783; ^1H NMR (400 MHz, DMSO- d_6) δ (ppm) 9.89 (s, 1H), 8.70 (s, 1H), 8.21 (d, $J = 2.3$ Hz, 1H), 7.72 (m, 2H), 7.55 (m, 2H), 7.18 (m, 2H), 6.89–6.85 (m, 2H); ^{13}C NMR (100 MHz, DMSO- d_6) δ (ppm) 155.3 ($^1J = 233.10$ Hz), 152.3, 150.7, 148.4, 145.5, 141.7, 139.6, 130.7, 128.5 ($^2J = 31.6$ Hz), 125.6 ($^3J = 3.6$ Hz), 124.6 ($^1J = 270.40$ Hz), 121.3, 118.5 ($^2J = 24.00$ Hz), 118.4 ($^3J = 8.2$ Hz), 117.7 ($^2J = 24.3$ Hz), 117.3 ($^3J = 8.1$ Hz), 97.1. HRMS (ESI): m/z [M+H] $^+$ calculated for $\text{C}_{19}\text{H}_{13}\text{F}_4\text{N}_3\text{O}$: 374.0916; found: 374.0914.

Antifungal bioassay

Mycelium growth rate method [22] was adopted to evaluate the antifungal activities of the new pyrazolo[1,5-a]pyrimidine derivatives (**3** and **4**) against five different phytopathogenic fungi *in vitro*, namely *Cytospora* sp., *Colletotrichum gloeosporioides*, *Botrytis cinerea*, *Alternaria*

solani, and *Fusarium solani*. All of the five kinds of fungi were incubated on PDA and cultured for 7 days at 28 °C until their mycelia grew well. An acetone solution of each sample (**3** and **4**) was added into sterilized Petri dishes that contained about 20 mL sterile molten PDA agar medium and mixed to the final certain concentration. Every kind of mycelium with medium was cut to 4 mm diameter, placed in the center of the dishes with aseptic technique, and grew at 28 °C for 4 days. All of the antifungal tests for compounds **3** and **4** were performed in triplicate. Acetone was used as a negative control and the commercial fungicide hymexazol as a positive control.

The diameters of the mycelia were measured after complete growth. The mycelial growth inhibition rate was calculated by the following formula:

Mycelia growth inhibition rate (%)

$$= (C - T)/(C - 4) \times 100 \%,$$

where *C* stands for the average diameter of mycelia of negative control test and *T* stands for the average diameter of mycelia on other treated PDA, which were expressed in mm [23].

Acknowledgments This research was supported by the National Natural Science Foundation of China (No. 21542002) and Innovation Funds of Graduate Programs of Shaanxi Normal University (No. 2016CBY002).

References

- Yang R, Gao ZF, Zhao JY (2015) New Class of 2-aryl-6-chloro-3,4-dihydroisoquinolinium salts as potential antifungal agents for plant protection: synthesis, bioactivity and structure–activity relationships. *J Agric Food Chem* 63:1906–1914. doi:10.1021/jf505609z
- Bräse S, Encinas A, Keck J (2009) Chemistry and biology of mycotoxins and related fungal metabolites. *Chem Rev* 109:3903–3990. doi:10.1021/cr050001f
- Znini M, Cristofari G, Majidi L (2013) In vitro antifungal activity and chemical composition of *Warionia saharae* essential oil against 3 apple phytopathogenic fungi. *Food Sci Biotechnol* 22:113–119. doi:10.1007/s10068-013-0056-2
- Sheng C, Xu H, Wang W (2010) Design, synthesis and antifungal activity of isosteric analogues of benzoheterocyclic N-myristoyltransferase inhibitors. *Eur J Med Chem* 45:3531–3540. doi:10.1016/j.ejmech.2010.03.007
- Vernekar JV, Ghatge MS, Deshpande VV (1999) Alkaline protease inhibitor: a novel class of antifungal proteins against phytopathogenic fungi. *Biochem Biophys Res Commun* 262:702–707. doi:10.1006/bbrc.1999.1269
- Feurer A, Luithle J, Wirtz S (2004) Novel 2,5-disubstituted pyrimidine derivatives. PCT international applications. WO Patent 2,004,009,589
- Senga K, Novinson T, Springer RH (1975) Synthesis and antitrichomonal activity of certain pyrazolo[1,5-*a*] pyrimidines. *J Med Chem* 18:312–314. doi:10.1021/jm00237a021
- Novinson T, Robins RK, Matthews TR (1977) Synthesis and antifungal properties of certain 7-alkylaminopyrazolo[1,5-*a*] pyrimidines. *J Med Chem* 20:296–299. doi:10.1021/jm00212a021
- Saggar S, Sisko J, Tucker T (2007) Acoustic alert communication system with enhanced signal to noise. US Patent Application 2,007,021,442
- Vicentini CB, Romagnoli C, Andreotti E (2007) Synthetic pyrazole derivatives as growth inhibitors of some phytopathogenic fungi. *J Agric Food Chem* 55:10331–10338. doi:10.1021/jf072077d
- Cui F, Chai T, Liu X (2016) Toxicity of three strobilurins (kresoxim-methyl, pyraclostrobin and trifloxystrobin) on *Daphnia magna*. *Environ Toxicol Chem* 9999:1–8. doi:10.1002/etc.3520
- Yoshikawa Y, Katsuta H, Kishi J (2011) Structure–activity relationship of carboxin-related carboxamides as fungicide. *J Pestic Sci* 36:347–356. doi:10.1584/jpestics.G10-70
- Huppatz JL (1985) Systemic fungicides. The synthesis of pyrazolo[1,5-*a*]pyrimidine analogues of carboxin. *Aust J Chem* 38:221–230. doi:10.1071/CH9850221
- Giori P, Poli T, Vicentini CB (1985) Synthesis and antifungal activity of pyrazolo[3,4-*d*]pyrimidin-4(5*H*)-thiones. *Farm Ed Sci* 40:795–802. doi:10.1002/chin.198615273
- Vicentini CB, Forlani G, Manfrini M, Romagnoli C, Mares D (2002) Development of new fungicides against *Magnaporthe grisea*: synthesis and biological activity of pyrazolo[3,4-*d*]thiazine, pyrazolo[1,5-*c*] [1,3,5]thiadiazine, and pyrazolo[3,4-*d*]pyrimidine derivatives. *J Agric Food Chem* 50:4839–4845. doi:10.1021/jf0202436
- Daniels R, Kim K, Lebois E, Muchalski H, Hughes M, Lindsley C (2008) Microwave-assisted protocols for the expedited synthesis of pyrazolo[1,5-*a*]pyrimidine and [3,4-*d*]pyrimidines. *Tetrahedron Lett* 49:305–310. doi:10.1016/j.tetlet.2007.11.054
- Quiroga J, Portilla J, Aboní'a R, Insuasty B, Noguera M, Cobo J (2007) Regioselective synthesis of novel polyfunctionally substituted pyrazolo[1,5-*a*]pyrimidines under solvent-free conditions. *Tetrahedron Lett* 48:6352–6355. doi:10.1016/j.tetlet.2007.07.041
- Zhang ZT, Ma YQ, Liang Y, Xue D, He Q (2011) An efficient one-pot synthesis of diarylpyrazolo[1,5-*a*]pyrimidine from isoflavones. *J Heterocycl Chem* 48:279–285. doi:10.1002/jhet.546
- Giguere RJ, Bray TL, Duncan SM (1986) Application of commercial microwave ovens to organic synthesis. *Tetrahedron Lett* 27:4945–4948. doi:10.1016/S0040-4039(00)85103-5
- Gedye R, Smith F, Westaway K (1986) The use of microwave ovens for rapid organic synthesis. *Tetrahedron Lett* 27:279–282. doi:10.1016/S0040-4039(00)83996-9
- Dao P, Garbay C, Chen H (2012) High yielding microwave-assisted synthesis of tri-substituted 1,3,5-triazines using Pd-catalyzed aryl and heteroarylation. *Tetrahedron* 68:3856–3860. doi:10.1016/j.tet.2012.03.041
- Bai YB, Zhang AL, Tang JJ, Gao JM (2013) Synthesis and antifungal activity of 2-chloromethyl-1*H*-benzimidazole derivatives against phytopathogenic fungi in vitro. *J Agric Food Chem* 61:2789–2795. doi:10.1021/jf3053934
- Xu H, Fan L (2011) Antifungal agents. Part 4: synthesis and antifungal activities of novel indole [1,2-*c*]-1,2,4-benzotriazine derivatives against phytopathogenic fungi in vitro. *Eur J Med Chem* 46:364–369. doi:10.1016/j.ejmech.2010.10.022